Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roll-over study of dabrafenib and/or trametinib in patients who completed a prior Novartis/GSK study
NCT03340506Phase 4Recruiting
- Sponsor
- Novartis
- Start
- Jan 2018
- Primary completion
- Dec 2032
- Countries
- 15
01
Overview
A Phase 4 trial of dabrafenib + trametinib, trametinib in melanoma, non-small cell lung cancer (NSCLC), solid tumor, rare cancers, high-grade glioma (HGG), sponsored by Novartis. Started Jan 2018; status: recruiting.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
melanomanon-small cell lung cancer (NSCLC)solid tumorrare cancershigh-grade glioma (HGG)
Beyond the preview
Go deeper on NCT03340506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03340506.